Biotech: Page 2

  • The Biogen logo is displayed on wall inside the company's Cambridge, Massachusetts, headquarters on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    At JPM, Biogen CEO tries to take down the deal temperature

    While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his company to go after larger deals.

    By • Jan. 15, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    J&J files a potential blockbuster; Lykos shakes up its board

    The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong revenue numbers, while Bausch + Lomb made an acquisition.

    By BioPharma Dive team • Jan. 15, 2025
  • Colorized scanning electron micrograph of a natural killer cell from a human donor. Explore the Trendline➔
    Image attribution tooltip
    National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    Trendline

    Cell therapy

    The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

    By BioPharma Dive staff
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive
    Image attribution tooltip

    JPM25: Amgen’s defense, Merck’s patent ‘hill’ and Viking’s long-term planning

    Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

    By , , • Jan. 14, 2025
  • A 3D illustration of an adeno-associated virus.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku

    Nippon Shinyaku will pay Regenxbio $110 million upfront for U.S. and Asia rights to treatments for Hunter and Hurler syndromes.

    By • Jan. 14, 2025
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Honglouwawa via Getty Images
    Image attribution tooltip

    5 questions facing emerging biotech in 2025

    Young drugmakers confront several harsh realities this year, among them a contracting sector and competition from China.

    By , , • Jan. 14, 2025
  • An image for JPM2020 snippets articles
    Image attribution tooltip
    Danielle Ternes / BioPharma Dive
    Image attribution tooltip

    JPM25: Deals, Summit’s bravado and gene therapy headwinds

    Drug executives talked M&A and the incoming administration, but also weighed the outlook for cell and gene therapy developers after a difficult year. 

    By , , • Updated Jan. 14, 2025
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street

    Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's also unlikely to appease broader investor concerns.

    By • Jan. 13, 2025
  • The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip

    Moderna shares tumble on slashed sales guidance

    The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.

    By • Jan. 13, 2025
  • An illustration of DNA methylation colored in white, blue and red.
    Image attribution tooltip
    Selvanegra via Getty Images
    Image attribution tooltip
    Gene editing

    Tune raises $175M for hepatitis B medicine, epigenetic research

    The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat chronic hepatitis B infections.

    By • Jan. 12, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assets

    Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

    By BioPharma Dive staff • Jan. 10, 2025
  • Intellia Therapeutics
    Image attribution tooltip
    Permission granted by Intellia Therapeutics
    Image attribution tooltip

    Intellia to stop work on rare disease therapy, lay off staff

    The CRISPR company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

    By • Jan. 10, 2025
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    Ouro, backed by GSK, joins hunt to bring bispecifics to autoimmune disease

    “Practice of medicine could fundamentally change with these types of therapies,” said CEO Jaideep Dudani.

    By • Jan. 10, 2025
  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Stadtratte via Getty Images
    Image attribution tooltip

    Healthcare venture capital investment boosted by AI in 2024: report

    Nearly 30% of the funding poured into healthcare startups last year, including for biotechs, went to companies leveraging artificial intelligence, according to Silicon Valley Bank.

    By Emily Olsen • Jan. 9, 2025
  • A person in a white sweater holds a drug injection pen.
    Image attribution tooltip
    CR via Getty Images
    Image attribution tooltip

    Verdiva starts up with $411M and a portfolio of obesity drugs from China

    The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind Biosciences, led by an oral therapy ready for Phase 2 testing.

    By Kristin Jensen • Jan. 9, 2025
  • A composite image of two headshots, featuring Maze CEO Jason Coloma and CMO Harold Bernstein.
    Image attribution tooltip
    Permission granted by Maze Therapeutics
    Image attribution tooltip

    Kidney disease drugmaker Maze files for IPO

    Maze fits the mold of biotechs that have pulled off successful offerings recently: The seven-year old startup, which raised about $500 million privately, has a drug in Phase 2 testing.

    By • Jan. 8, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

    The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative reaction to data for its hives drug and Stoke finalized Phase 3 trial plans.

    By BioPharma Dive staff • Jan. 8, 2025
  • A photo of Galapagos' offices.
    Image attribution tooltip
    Courtesy of Galapagos
    Image attribution tooltip

    Galapagos, after research struggles, will split in two and revamp Gilead deal

    Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its current workforce.

    By Kristin Jensen • Jan. 8, 2025
  • The Vertex Pharmaceuticals building in daylight on the Boston Seaport.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex, startup Orna to partner on gene editing research

    The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

    By • Jan. 7, 2025
  • Drug injection pens and vials are arranged on a wooden table.
    Image attribution tooltip
    Douglas Cliff via Getty Images
    Image attribution tooltip

    Metsera reveals data supporting long-acting obesity shot

    The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug as a future threat to weight loss medicines from Novo Nordisk and Eli Lilly. 

    By • Jan. 7, 2025
  • Premises of Novo Holdings in Hellerup, Denmark
    Image attribution tooltip
    Courtesy of Novo Holdings
    Image attribution tooltip

    Orbis raises $93M to turn popular biologics into pills

    The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against “validated blockbuster biologic targets.”

    By • Jan. 6, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals

    Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got long-awaited data and BioNTech settled with the NIH.

    By BioPharma Dive staff • Jan. 2, 2025
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Ionis gets a milestone approval; Another top FDA official to step down

    The clearance of Tryngolza gives Ionis its first wholly-owned, marketed medicine. Elsewhere, Robert Temple became the latest FDA leader to leave the agency, and two biotechs cut research deals.

    By BioPharma Dive staff • Dec. 20, 2024
  • A clear drop with a dollar symbol is pipetted into a test tube.
    Image attribution tooltip
    ADragan via Getty Images
    Image attribution tooltip

    A venture firm breathes new life into an old NGM drug

    A startup formed by KdT Ventures intends to test the drug, which was once licensed to Merck and evaluated in multiple metabolic disorders, for an unspecified rare condition.

    By • Dec. 19, 2024
  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex ‘ends the year in pain’ as latest non-opioid drug data disappoint

    Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ahead in the indication.

    By • Dec. 19, 2024
  • A man in a suit and tie speaks during a press conference.
    Image attribution tooltip

    Kyodo/Newscom

    Image attribution tooltip

    Ottimo raises $140M to compete in chase for new type of cancer drug

    Led by former Seagen CEO David Epstein, the startup claims it has a drug that could stand out from other PD1- and VEGF-blocking cancer treatments.

    By • Dec. 19, 2024